Our Pricing

Cheapest Wegovy UK: From £69.00 with Fast Delivery

Published on: June 03, 2026

Looking for the cheapest Wegovy UK online pharmacy with transparent pricing and genuine UK-licensed medication? At Cured Pharmacy, Wegovy starts from £79.00 with free clinical consultation, discreet packaging, and fast delivery across the UK. Our UK-registered prescribers assess every patient individually, ensuring safe, personalised weight loss treatment under full GPhC regulation.

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a GLP-1 receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with weight-related comorbidities [1]. Semaglutide mimics a natural hormone called glucagon-like peptide-1, which regulates appetite and food intake by acting on brain regions that control hunger.

In the landmark STEP 1 trial, participants using Wegovy achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. The medication works by slowing gastric emptying, reducing appetite, and improving glycaemic control, making it easier for patients to maintain a reduced-calorie diet and achieve sustainable weight loss [2].

Wegovy is administered as a once-weekly subcutaneous injection, with doses gradually increased over 16-20 weeks to minimise gastrointestinal side effects. The maintenance dose is typically 2.4 mg weekly, though your UK prescriber will determine the appropriate dosing schedule based on your individual response and tolerability.

Wegovy Pricing at Cured Pharmacy: Transparent and Competitive

The cost of Wegovy varies significantly across UK pharmacies, with many providers charging substantially higher rates for the same genuine medication. At Cured Pharmacy, our commitment to lowest prices guaranteed means you'll consistently find competitive rates without compromising on quality, safety, or regulatory compliance.

We understand that weight loss treatment represents a significant financial commitment, particularly as Wegovy is typically used for 12 months or longer to achieve optimal results. Our transparent pricing structure ensures you can budget effectively for your treatment journey, with clear costs displayed before you begin the free online consultation process.

Why Our Wegovy Prices Are Lower

At Cured Pharmacy, we guarantee the cheapest Wegovy UK pricing at £79.00 per pen, with no hidden fees or surprise charges. Unlike many providers who reveal costs only after consultation, we display transparent upfront pricing so you can make informed decisions before starting your clinical assessment.

Our pricing model eliminates unnecessary overheads by operating exclusively online, allowing us to pass savings directly to patients. Every Wegovy pen is sourced from UK-licensed wholesalers and dispensed by our GPhC-registered pharmacy (9012511) under the supervision of Superintendent Pharmacist Tarun Kumar (GPhC 2233073).

Wegovy vs Other Weight Loss Treatments Available in the UK

Semaglutide has been extensively studied in the STEP trial programme, which included over 4,500 participants across multiple studies [1][2]. The consistent efficacy demonstrated across diverse patient populations has established Wegovy as a first-line option for many UK prescribers treating obesity and weight-related health conditions.

Some patients may be considered for oral medications such as orlistat or combination therapies, though injectable GLP-1 receptor agonists generally produce superior weight loss outcomes in clinical trials. The choice between different treatment options should always be made in consultation with a qualified healthcare professional who can assess your individual circumstances.

Comparing Semaglutide to Alternative Medications

While Wegovy remains the most prescribed GLP-1 medication for weight loss in the UK, other licensed options include tirzepatide-based treatments and liraglutide injections. Each medication works through slightly different mechanisms, with varying efficacy profiles and dosing schedules that may suit different patient needs.

Your UK prescriber will consider your medical history, weight loss goals, previous treatment responses, and any contraindications when recommending the most appropriate medication. Factors such as injection frequency, side effect profiles, and cost all play important roles in treatment selection.

Clinical Evidence: STEP Trials and Real-World Outcomes

The STEP clinical trial programme represents the most comprehensive investigation of semaglutide for weight management, with five major studies examining efficacy, safety, and long-term outcomes [1][2]. STEP 1, the pivotal trial, demonstrated that 83.5% of participants achieved at least 5% weight loss, with 66.1% achieving 10% or greater reduction over 68 weeks [1].

STEP 2 specifically evaluated semaglutide in patients with type 2 diabetes, showing an average weight reduction of 9.6% compared to 3.4% with placebo [3]. This trial confirmed that Wegovy's efficacy extends to patients with metabolic comorbidities, not just those with obesity alone.

Real-world evidence from UK prescribing data suggests that patients who maintain treatment for at least 12 months experience sustained weight loss and improvements in cardiovascular risk factors, including blood pressure, lipid profiles, and glycaemic control [4]. However, individual results vary, and ongoing lifestyle modifications remain essential for optimal outcomes.

The STEP 4 trial examined weight maintenance after initial weight loss, finding that participants who continued semaglutide maintained their weight reduction, while those switched to placebo regained an average of 6.9% body weight [2]. This underscores the importance of sustained treatment for long-term weight management.

How to Start Wegovy Treatment at Cured Pharmacy

Wegovy is a prescription-only medication in the UK, meaning it cannot legally be supplied without clinical assessment by a UK-registered prescriber. This regulatory requirement exists to protect patient safety, as GLP-1 medications carry contraindications and require monitoring for certain populations, including those with personal or family history of thyroid cancer or multiple endocrine neoplasia syndrome type 2 [1].

Your prescriber will determine the appropriate starting dose and escalation schedule based on your individual circumstances. Standard dosing begins at 0.25 mg weekly for four weeks, gradually increasing to the maintenance dose of 2.4 mg over 16-20 weeks. This titration schedule minimises gastrointestinal side effects such as nausea, which are most common during dose increases.

Ongoing support is available from our clinical team throughout your treatment journey. We recommend regular monitoring of your weight, blood pressure, and any side effects, with prescribers available to adjust dosing or provide guidance if needed. Sustainable weight loss requires combining medication with dietary modifications and increased physical activity for best results.

Free Online Consultation Process

Starting your Wegovy treatment takes under 3 minutes with our streamlined online consultation. You'll complete a confidential medical questionnaire covering your weight history, current medications, medical conditions, and weight loss goals. Our UK-registered prescribers review every submission individually, ensuring treatment suitability and safety.

If approved, your prescription is sent directly to our GPhC-registered pharmacy for dispensing. We use 100% discreet packaging with no external branding, and medications are dispatched via fast, tracked delivery services across the UK. Most patients receive their first Wegovy pen within 2-3 working days of prescription approval.

Safety, Side Effects, and Patient Suitability for Wegovy

Wegovy is not suitable for everyone. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, previous serious hypersensitivity to semaglutide, pregnancy, and breastfeeding [1]. Patients with a history of pancreatitis, severe gastrointestinal disease, or diabetic retinopathy should discuss potential risks with their prescriber.

Rare but serious side effects include pancreatitis, gallbladder problems, kidney injury, and hypoglycaemia (particularly in patients taking other glucose-lowering medications). Warning signs of pancreatitis include severe abdominal pain radiating to the back, nausea, and vomiting — seek immediate medical attention if these occur [1].

Clinical trials and post-marketing surveillance have identified a potential increased risk of thyroid C-cell tumours in rodent studies, though this has not been confirmed in humans [1]. As a precautionary measure, patients with relevant risk factors are typically excluded from treatment. Your UK prescriber will conduct a thorough risk assessment before prescribing Wegovy to ensure it's safe and appropriate for your individual circumstances.

Common Side Effects and How to Manage Them

The most frequently reported side effects of Wegovy are gastrointestinal, including nausea, vomiting, diarrhoea, constipation, and abdominal discomfort [1]. These effects are typically mild to moderate, most common during dose escalation, and tend to decrease over time as the body adjusts to treatment.

To minimise gastrointestinal symptoms, eat smaller, more frequent meals, avoid high-fat foods, and stay well-hydrated. If nausea persists or becomes severe, contact your prescriber, who may recommend slowing the dose escalation schedule or providing anti-nausea medication. Most patients find these side effects manageable and temporary.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., Dicker, D., & STEP 4 Investigators. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
3. Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., Lingvay, I., & STEP 2 Study Group. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
4. Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., Wharton, S., & STEP 5 Study Group. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to treatment, lifestyle modifications, and individual patient factors.